María Pilar
Garrido López
Profesor/a Asociado/a en CC. de la Salud
Hospital Universitario La Paz
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario La Paz (39)
2024
-
Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology
Scientific Reports, Vol. 14, Núm. 1
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
-
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium
Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362
2023
-
European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 1-7
2022
-
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program
Oncotarget, Vol. 13, Núm. 1, pp. 812-827
2020
-
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
BMC Psychology, Vol. 8, Núm. 1
-
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 759-771
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 167-181
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 22, Núm. 7, pp. 989-1003
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
-
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296
-
Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non–small cell lung cancer: Efficacy, safety, and biomarkers
Clinical Cancer Research, Vol. 25, Núm. 1, pp. 64-72
2017
-
A consensus statement on the gender perspective in lung cancer
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535
-
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database
Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1537-1542
-
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226
2016
-
Lung cancer in women with a family history of cancer: The Spanish female-specific database WORLD07
Anticancer Research, Vol. 36, Núm. 12, pp. 6647-6653
2015
-
Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Españ
Revista Espanola de Patologia
-
Therapeutic potential of denosumab in patients with lung cancer: Beyond prevention of skeletal complications
Clinical Lung Cancer, Vol. 16, Núm. 6, pp. 431-446
2014
-
Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry
PLoS ONE, Vol. 9, Núm. 9
-
Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 103-112